Drug
CX-4945
CX-4945 is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
67%(2 trials)
Phase Distribution
Ph phase_1
4
100%
Phase Distribution
4
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
4(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(3)
Other(1)
Detailed Status
Completed3
unknown1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 1
Trials by Phase
Phase 14 (100.0%)
Trials by Status
unknown125%
completed375%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_1
Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)
NCT03897036
completedphase_1
A Study of Silmitasertib (CX-4945) in Healthy Subject
NCT05817708
completedphase_1
Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma
NCT02128282
unknownphase_1
Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma
NCT01199718
Clinical Trials (4)
Showing 4 of 4 trials
NCT03897036Phase 1
Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)
NCT05817708Phase 1
A Study of Silmitasertib (CX-4945) in Healthy Subject
NCT02128282Phase 1
Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma
NCT01199718Phase 1
Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4